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Sir,
We thank Khan et al (2011) for their valuable and insightful
comments on our study (Mazouni et al, 2011) expounded in their
Letter to the Editor (Khan et al, 2011).
In our initial publication, we demonstrated the presence of the
Epstein–Barr virus (EBV) in malignant breast tumours, which is con-
sistent with findings in previous international publications (Fina et al,
2001). In the paper, they are referring to, we observed the same
positivity rate as previously noted using a more precise PCR
technology. Khan et al (2011) suggest that the positivity findings in
BC specimens may have been biased by EBV-infected lymphocytes.
As mentioned in our paper, our aim was to ascertain the presence of
EBV in epithelial cells by isolating these cells using laser
microdissection capture (LMC) (Mazouni et al,2 0 1 1 ) .Al a r g e
amount of tissue (100mg) was used to extract DNA from our
specimens and this might explain why EBV was detected at a higher
frequency than in other studies. In their study, Khan et al (2010) did
not perform LMC to ensure the validity of epithelial cell positivity.
Besides, another valuable criticism leveled by Khan et al (2010)
concerns the controversial association between EBV and BC. Other
retroviruses have been reported to induce BC. In a previous report,
Berebbi et al (1990) induced the development of BC in an
experimental model by modulating the presence of the polyoma
virus during the development of the mammary gland . Moreover,
the relationship between EBV and BC has been suggested in an
epidemiological study (Yasui et al, 2001).
The aggressive profile of EBV-positive BC that we observed has
previously been reported in other series (Bonnet et al, 1999;
Murray et al, 2003). Moreover, the differentiation markers
evaluated in the breast specimens are associated with the epithelial
component.
Finally, we agree that EBV is a ubiquitous infection that makes
the physiopathology of BC development difficult to explain. There
is still a long road ahead in the field of virus-related cancer before
we will be able to formally assess their role and propose
prevention.
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